Forte Biosciences (FBRX)
(Delayed Data from NSDQ)
$0.53 USD
-0.02 (-3.44%)
Updated Aug 2, 2024 04:00 PM ET
After-Market: $0.53 0.00 (-0.02%) 7:58 PM ET
3-Hold of 5 3
D Value C Growth D Momentum F VGM
Income Statements
Fiscal Year end for Forte Biosciences, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 0 | 0 | 0 | 0 | 0 |
Cost Of Goods | 0 | 0 | 0 | 0 | 0 |
Gross Profit | 0 | 0 | 0 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 32 | 14 | 21 | 46 | 62 |
Income After Depreciation & Amortization | -32 | -14 | -21 | -46 | -62 |
Non-Operating Income | 1 | 0 | 0 | 0 | 2 |
Interest Expense | 0 | 0 | 0 | 0 | 4 |
Pretax Income | -31 | -14 | -22 | -46 | -64 |
Income Taxes | 0 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | -31 | -14 | -22 | -46 | -64 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | -31 | -14 | -22 | -46 | -64 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -32 | -14 | -21 | -46 | -61 |
Depreciation & Amortization (Cash Flow) | 0 | 0 | 0 | 0 | 1 |
Income After Depreciation & Amortization | -32 | -14 | -21 | -46 | -62 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 31.57 | 17.38 | 13.97 | 7.36 | 1.58 |
Diluted EPS Before Non-Recurring Items | -1.00 | -0.80 | -1.55 | -6.32 | -40.33 |
Diluted Net EPS (GAAP) | -1.00 | -0.80 | -1.55 | -6.32 | -40.33 |
Fiscal Year end for Forte Biosciences, Inc falls in the month of December .
All items in Millions except EPS data.
6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 | |
---|---|---|---|---|---|
Sales | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Cost Of Goods | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Gross Profit | NA | 0.00 | 0.00 | 0.00 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 0.00 | 7.80 | 6.38 | 10.22 | 9.04 |
Income After SG&A, R&D, and Dept/Amort Expenses | 0.00 | -7.80 | -6.38 | -10.22 | -9.04 |
Non-Operating Income | NA | 0.38 | -0.62 | 0.26 | 0.14 |
Interest Expense | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | NA | -7.42 | -5.87 | -9.96 | -8.90 |
Income Taxes | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Minority Interest | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | NA | -7.42 | -5.87 | -9.96 | -8.90 |
Extras & Discontinued Operations | NA | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | NA | -7.42 | -5.87 | -9.96 | -8.90 |
Earnings Per Share Data | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | 6/30/23 |
---|---|---|---|---|---|
Average Shares | NA | 46.08 | 31.57 | 37.86 | 21.05 |
Diluted EPS Before Non-Recurring Items | NA | -0.16 | -0.04 | -0.26 | -0.42 |
Diluted Net EPS (GAAP) | NA | -0.16 | 0.00 | -0.26 | -0.42 |